Literature DB >> 18596105

Central role of reverting mutations in HLA associations with human immunodeficiency virus set point.

Philippa C Matthews1, Andrew Prendergast, Alasdair Leslie, Hayley Crawford, Rebecca Payne, Christine Rousseau, Morgane Rolland, Isobella Honeyborne, Jonathan Carlson, Carl Kadie, Christian Brander, Karen Bishop, Nonkululeko Mlotshwa, James I Mullins, Hoosen Coovadia, Thumbi Ndung'u, Bruce D Walker, David Heckerman, Philip J R Goulder.   

Abstract

Much uncertainty still exists over what T-cell responses need to be induced by an effective human immunodeficiency virus (HIV) vaccine. Previous studies have hypothesized that the effective CD8(+) T-cell responses are those driving the selection of escape mutations that reduce viral fitness and therefore revert post-transmission. In this study, we adopted a novel approach to define better the role of reverting escape mutations in immune control of HIV infection. This analysis of sequences from 710 study subjects with chronic C-clade HIV type 1 infection demonstrates the importance of mutations that impose a fitness cost in the control of viremia. Consistent with previous studies, the viral set points associated with each HLA-B allele are strongly correlated with the number of Gag-specific polymorphisms associated with the relevant HLA-B allele (r = -0.56, P = 0.0034). The viral set points associated with each HLA-C allele were also strongly correlated with the number of Pol-specific polymorphisms associated with the relevant HLA-C allele (r = -0.67, P = 0.0047). However, critically, both these correlations were dependent solely on the polymorphisms identified as reverting. Therefore, despite the inevitable evolution of viral escape, viremia can be controlled through the selection of mutations that are detrimental to viral fitness. The significance of these results is in highlighting the rationale for an HIV vaccine that can induce these broad responses.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18596105      PMCID: PMC2519667          DOI: 10.1128/JVI.00580-08

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  44 in total

1.  HLA and AIDS: a cautionary tale.

Authors:  S J O'Brien; X Gao; M Carrington
Journal:  Trends Mol Med       Date:  2001-09       Impact factor: 11.951

2.  Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection.

Authors:  Marcus Altfeld; Marylyn M Addo; Eric S Rosenberg; Frederick M Hecht; Paul K Lee; Martin Vogel; Xu G Yu; Rika Draenert; Mary N Johnston; Daryld Strick; Todd M Allen; Margaret E Feeney; James O Kahn; Rafick P Sekaly; Jay A Levy; Jürgen K Rockstroh; Philip J Goulder; Bruce D Walker
Journal:  AIDS       Date:  2003-12-05       Impact factor: 4.177

3.  Reversion of CTL escape-variant immunodeficiency viruses in vivo.

Authors:  Thomas C Friedrich; Elizabeth J Dodds; Levi J Yant; Lara Vojnov; Richard Rudersdorf; Candice Cullen; David T Evans; Ronald C Desrosiers; Bianca R Mothé; John Sidney; Alessandro Sette; Kevin Kunstman; Steven Wolinsky; Michael Piatak; Jeffrey Lifson; Austin L Hughes; Nancy Wilson; David H O'Connor; David I Watkins
Journal:  Nat Med       Date:  2004-02-15       Impact factor: 53.440

4.  Potential underestimation of HLA-C-restricted cytotoxic T-lymphocyte responses.

Authors:  P J Goulder; M Bunce; G Luzzi; R E Phillips; A J McMichael
Journal:  AIDS       Date:  1997-12       Impact factor: 4.177

5.  Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA.

Authors:  Photini Kiepiela; Alasdair J Leslie; Isobella Honeyborne; Danni Ramduth; Christina Thobakgale; Senica Chetty; Prinisha Rathnavalu; Corey Moore; Katja J Pfafferott; Louise Hilton; Peter Zimbwa; Sarah Moore; Todd Allen; Christian Brander; Marylyn M Addo; Marcus Altfeld; Ian James; Simon Mallal; Michael Bunce; Linda D Barber; James Szinger; Cheryl Day; Paul Klenerman; James Mullins; Bette Korber; Hoosen M Coovadia; Bruce D Walker; Philip J R Goulder
Journal:  Nature       Date:  2004-12-09       Impact factor: 49.962

6.  Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA.

Authors:  G S Ogg; X Jin; S Bonhoeffer; P R Dunbar; M A Nowak; S Monard; J P Segal; Y Cao; S L Rowland-Jones; V Cerundolo; A Hurley; M Markowitz; D D Ho; D F Nixon; A J McMichael
Journal:  Science       Date:  1998-03-27       Impact factor: 47.728

7.  HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors.

Authors:  S A Migueles; M S Sabbaghian; W L Shupert; M P Bettinotti; F M Marincola; L Martino; C W Hallahan; S M Selig; D Schwartz; J Sullivan; M Connors
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-14       Impact factor: 11.205

8.  Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level.

Authors:  Corey B Moore; Mina John; Ian R James; Frank T Christiansen; Campbell S Witt; Simon A Mallal
Journal:  Science       Date:  2002-05-24       Impact factor: 47.728

9.  The differential ability of HLA B*5701+ long-term nonprogressors and progressors to restrict human immunodeficiency virus replication is not caused by loss of recognition of autologous viral gag sequences.

Authors:  Stephen A Migueles; Alisha C Laborico; Hiromi Imamichi; W Lesley Shupert; Cassandra Royce; Mary McLaughlin; Linda Ehler; Julia Metcalf; Shuying Liu; Claire W Hallahan; Mark Connors
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

10.  HIV evolution: CTL escape mutation and reversion after transmission.

Authors:  A J Leslie; K J Pfafferott; P Chetty; R Draenert; M M Addo; M Feeney; Y Tang; E C Holmes; T Allen; J G Prado; M Altfeld; C Brander; C Dixon; D Ramduth; P Jeena; S A Thomas; A St John; T A Roach; B Kupfer; G Luzzi; A Edwards; G Taylor; H Lyall; G Tudor-Williams; V Novelli; J Martinez-Picado; P Kiepiela; B D Walker; P J R Goulder
Journal:  Nat Med       Date:  2004-02-08       Impact factor: 53.440

View more
  108 in total

1.  Impact of HLA-B*81-associated mutations in HIV-1 Gag on viral replication capacity.

Authors:  Jaclyn K Wright; Vanessa L Naidoo; Zabrina L Brumme; Jessica L Prince; Daniel T Claiborne; Philip J R Goulder; Mark A Brockman; Eric Hunter; Thumbi Ndung'u
Journal:  J Virol       Date:  2012-01-11       Impact factor: 5.103

Review 2.  Primary drug resistance in South Africa: data from 10 years of surveys.

Authors:  Justen Manasa; David Katzenstein; Sharon Cassol; Marie-Louise Newell; Tulio de Oliveira
Journal:  AIDS Res Hum Retroviruses       Date:  2012-03-12       Impact factor: 2.205

3.  Long-term control of HIV-1 in hemophiliacs carrying slow-progressing allele HLA-B*5101.

Authors:  Yuka Kawashima; Nozomi Kuse; Hiroyuki Gatanaga; Takuya Naruto; Mamoru Fujiwara; Sachi Dohki; Tomohiro Akahoshi; Katsumi Maenaka; Philip Goulder; Shinichi Oka; Masafumi Takiguchi
Journal:  J Virol       Date:  2010-04-21       Impact factor: 5.103

4.  CD8+ T cell escape mutations in simian immunodeficiency virus SIVmac239 cause fitness defects in vivo, and many revert after transmission.

Authors:  Philip A Mudd; Adam J Ericsen; Andrew D Walsh; Enrique J León; Nancy A Wilson; Nicholas J Maness; Thomas C Friedrich; David I Watkins
Journal:  J Virol       Date:  2011-09-28       Impact factor: 5.103

5.  Influence of Gag-protease-mediated replication capacity on disease progression in individuals recently infected with HIV-1 subtype C.

Authors:  Jaclyn K Wright; Vladimir Novitsky; Mark A Brockman; Zabrina L Brumme; Chanson J Brumme; Jonathan M Carlson; David Heckerman; Bingxia Wang; Elena Losina; Mopo Leshwedi; Mary van der Stok; Lungile Maphumulo; Nompumelelo Mkhwanazi; Fundisiwe Chonco; Philip J R Goulder; Max Essex; Bruce D Walker; Thumbi Ndung'u
Journal:  J Virol       Date:  2011-02-02       Impact factor: 5.103

6.  HLA-associated viral mutations are common in human immunodeficiency virus type 1 elite controllers.

Authors:  Toshiyuki Miura; Chanson J Brumme; Mark A Brockman; Zabrina L Brumme; Florencia Pereyra; Brian L Block; Alicja Trocha; Mina John; Simon Mallal; P Richard Harrigan; Bruce D Walker
Journal:  J Virol       Date:  2009-01-19       Impact factor: 5.103

7.  Evolutionary gamut of in vivo Gag substitutions during early HIV-1 subtype C infection.

Authors:  Vladimir Novitsky; Rui Wang; Jeannie Baca; Lauren Margolin; Mary F McLane; Sikhulile Moyo; Erik van Widenfelt; Joseph Makhema; M Essex
Journal:  Virology       Date:  2011-10-19       Impact factor: 3.616

Review 8.  HLA-C as a mediator of natural killer and T-cell activation: spectator or key player?

Authors:  Marie-Eve Blais; Tao Dong; Sarah Rowland-Jones
Journal:  Immunology       Date:  2011-03-01       Impact factor: 7.397

9.  CD8+ TCR Bias and Immunodominance in HIV-1 Infection.

Authors:  Henrik N Kløverpris; Reuben McGregor; James E McLaren; Kristin Ladell; Mikkel Harndahl; Anette Stryhn; Jonathan M Carlson; Catherine Koofhethile; Bram Gerritsen; Can Keşmir; Fabian Chen; Lynn Riddell; Graz Luzzi; Alasdair Leslie; Bruce D Walker; Thumbi Ndung'u; Søren Buus; David A Price; Philip J Goulder
Journal:  J Immunol       Date:  2015-04-24       Impact factor: 5.422

10.  Impact of HLA in mother and child on disease progression of pediatric human immunodeficiency virus type 1 infection.

Authors:  Christina F Thobakgale; Andrew Prendergast; Hayley Crawford; Nompumelelo Mkhwanazi; Danni Ramduth; Sharon Reddy; Claudia Molina; Zenele Mncube; Alasdair Leslie; Julia Prado; Fundi Chonco; Wendy Mphatshwe; Gareth Tudor-Williams; Prakash Jeena; Natasha Blanckenberg; Krista Dong; Photini Kiepiela; Hoosen Coovadia; Thumbi Ndung'u; Bruce D Walker; Philip J R Goulder
Journal:  J Virol       Date:  2009-07-15       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.